Telmisartan Versus Ramipril After Acute Coronary Syndrome

• Status: Unknown status
• Trial end date: 2008-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the antinflammatory and endothelial progenitor cell (EPC) mobilizing effect of Ramipril and Telmisartan in patients presenting with acute coronary syndrome

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Catholic University of the Sacred Heart
• Treatments: Ramipril; Telmisartan

Criteria

Inclusion Criteria:

• Biochemical evidence of myocardial infarction as indicated by elevation of cTnT,

• presence of ECG ischemic changes,

• angiographic evidence of a primary coronary event, such as plaque erosion and/or rupture, fissuring, or dissection at coronary angiography,

• successful coronary revascularization of at least one culprit coronary vessel.

Exclusion Criteria:

• Age>80 years, current ACE inhibitor or ARB treatment,

• ejection fraction <35%, infarction secondary to ischemia due to an imbalance of O2 supply and demand,

• ECG abnormalities that could affect the recognition of ST segment shift,

• recent or chronic infective or inflammatory diseases,

• malignancy, and myocardial infarction,

• surgery or trauma in the previous month.